高级搜索
顺铂和氟尿嘧啶交替腹腔灌注并ECF方案治疗原发性腹膜癌疗效观察[J]. 肿瘤防治研究, 2010, 37(01): 95-96. DOI: 10.3971/j.issn.1000-8578.2010.01.026
引用本文: 顺铂和氟尿嘧啶交替腹腔灌注并ECF方案治疗原发性腹膜癌疗效观察[J]. 肿瘤防治研究, 2010, 37(01): 95-96. DOI: 10.3971/j.issn.1000-8578.2010.01.026
Cisplatin and Fluorouracil Alternating Intraperitoneal Perfusion and ECF in Treatment of Primary Peritoneal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(01): 95-96. DOI: 10.3971/j.issn.1000-8578.2010.01.026
Citation: Cisplatin and Fluorouracil Alternating Intraperitoneal Perfusion and ECF in Treatment of Primary Peritoneal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(01): 95-96. DOI: 10.3971/j.issn.1000-8578.2010.01.026

顺铂和氟尿嘧啶交替腹腔灌注并ECF方案治疗原发性腹膜癌疗效观察

Cisplatin and Fluorouracil Alternating Intraperitoneal Perfusion and ECF in Treatment of Primary Peritoneal Carcinoma

  • 摘要: 目的 观察顺铂(DDP)、氟尿嘧啶(5-Fu)交替腹腔灌注并ECF(表阿霉素、顺铂、5-氟尿嘧啶)方案治疗原发性腹膜癌腹水控制效果及近期临床疗效、不良反应。 方法 DDP、5-Fu交替腹腔灌注并ECF方案静脉化疗,21天为一周期,共6~8周期,至少4周期评定疗效。 结果 15例患者,腹水控制率86.6%;总有效率(RR)86.6%,其中完全缓解(CR)26.6%,部分缓解(PR)60%;主要不良反应为Ⅱ~Ⅲ度骨髓抑制。 结论 顺铂、氟尿嘧啶交替腹腔灌注并ECF方案治疗原发性腹膜癌腹水控制效果好,近期疗效好,不良反应轻,治疗费用低,可作为原发性腹膜癌的一线治疗方案推广。

     

    Abstract: Objective To observe the ascites control effects and short-term clinical efficacy and toxicity in the treatment of primary peritoneal carcinoma with cisplatin (DDP), fluorouracil (5-Fu) alternating abdominal perfusion and systemic chemotherapy of ECF (epirubicin, cisplatin, 5- fluorouracil). Methods DDP,5-Fu alternating intraperitoneal perfusion plus ECF program intravenous chemotherapy, one cycle of 21 days for a total of 6~8 cycles, was evaluate at least after 4 cycles. Results In 15 cases, the ascites control rate was 86.6%, and the total effective rate (RR) 86.6%, including complete remission (CR) (26.6%), and partial remission (PR) (60%). The major toxicity was Ⅱ~Ⅲ myelosuppression. Conclusion DDP and 5-Fu alternating intraperitoneal perfusion plus ECF in the treatment of primary peritoneal carcinoma has better control of ascites and satisfactory short -term efficacy,slight toxicity light and low-cost. It can be used as first-line treatment programs for primary peritioneal carcinoma.

     

/

返回文章
返回